Halozyme Therapeutics, Inc.
HALO
$47.82
-$2.41-4.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 485.36M | 444.09M | 392.47M | 337.29M | 318.80M |
| Total Depreciation and Amortization | 81.56M | 81.31M | 81.59M | 81.81M | 82.11M |
| Total Amortization of Deferred Charges | 7.37M | 7.35M | 7.33M | 7.32M | 7.30M |
| Total Other Non-Cash Items | 32.93M | 35.59M | 62.30M | 58.29M | 53.76M |
| Change in Net Operating Assets | -103.36M | -89.28M | -140.74M | -64.72M | -30.93M |
| Cash from Operations | 503.86M | 479.06M | 402.95M | 419.99M | 431.03M |
| Capital Expenditure | -8.10M | -10.70M | -10.24M | -11.67M | -7.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -262.36M | -252.03M | -290.25M | -204.79M | -111.97M |
| Cash from Investing | -270.46M | -262.72M | -300.49M | -216.46M | -119.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Common Stock | 31.63M | 31.63M | 30.42M | 15.96M | 8.93M |
| Repurchase of Common Stock | -253.32M | -250.49M | -252.79M | -252.79M | -252.79M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -221.69M | -218.86M | -222.37M | -236.83M | -243.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.70M | -2.52M | -119.91M | -33.30M | 67.74M |